Clinical trials: Arthritis, Rheumatoid (RA)
Rheumatoid Arthritis
Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease
The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving but not fully responding to treatment with methotrexate…
- Trial name
- CREDO 2 (NCT02760407)
- Testing
- Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w
- Where
- 203 sites in United States, Argentina and 16 more
- Volunteers
- 1,648 people
- Sponsor
- R-Pharm International, LLC
Rheumatoid Arthritis
A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment
This multi-center, randomized, parallel-group, active-controlled, open-label study will evaluate the safety and efficacy of a shortened RoActemra/Actemra (tocilizumab) infusion time compared to the normal infusion time.
- Trial name
- NCT01468077
- Testing
- Tocilizumab
- Where
- 8 sites in Denmark, Iceland
- Volunteers
- 47 people
- Sponsor
- Hoffmann-La Roche
Recurrence (Disease Attribute)
Combination Therapy Prevents the Relapse of RA
This trial aims to compare the cost effective and effect of preventing recurrence by different treatment of TFP and HCQ combined SSZ for remittent RA.
- Trial name
- NCT02320630
- Testing
- Entanercept, HCQ, MTX
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Peking University First Hospital
Rheumatoid Arthritis
A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01
This is a continuation trial of LymphoStat-B™ to evaluate the long-term safety in subjects with Rheumatoid Arthritis that completed study LBRA01 and benefitted from treatment.
- Trial name
- NCT00583557
- Testing
- belimumab
- Where
- 48 sites in United States, Poland
- Volunteers
- 155 people
- Sponsor
- Human Genome Sciences Inc.
Moderate to Severe Rheumatoid Arthritis
A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)
The goal of this clinical trial is to evaluate the efficacy and safety of intravenous infusions of burfiralimab (hzVSF-v13) when added to Disease-Modifying Antirheumatic Drug (DMARD) treatment as Standard of Care (SOC) in…
- Trial name
- NCT06306339
- Testing
- Burfiralimab, SOC (Standard of care)
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- ImmuneMed, Inc.
Rheumatoid Arthritis (RA)
A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function.
- Trial name
- CLOSEUP (NCT04574492)
- Where
- 39 sites in Canada
- Volunteers
- 413 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
The Genetic and the Functional Study of DNA Repair System and the Susceptibility to Rheumatoid Arthritis
This study is valuable for the understanding the role of DNA repair system plays in the progression of rheumatoid arthritis and for the development of new therapeutic modality in the future.
- Trial name
- NCT01285336
- Where
- Taiwan
- Volunteers
- healthy volunteers welcome
- Sponsor
- China Medical University Hospital
Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc)
Combined Growth Differentiation Factor-15 (GDF-15) and Lung Ultrasound for ILD Screening in Rheumatoid Arthritis and Systemic Sclerosis
The goal of this observational study is to detect the lung affection in patients with Rheumatoid Arthritis(RA) or Systemic sclerosis (SSc) before appearance of symptoms(Subclinical) using combined diagnostic modalities which are…
- Conditions
- Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Interstitial Lung Disease (ILD)
- Trial name
- NCT07839221
- Testing
- Lung ultrasound, GDF-15 level (ELISA), CT scan
- Volunteers
- 110 people
- Sponsor
- Assiut University
COVID 19, Influenza
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with…
- Conditions
- COVID 19, Influenza, Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus
- Trial name
- CO2I2 (NCT06599658)
- Testing
- Inactivated influenza vaccine (IIV) at baseline, COVID-19 Vaccines at a 3-month interval, Inactivated influenza vaccine at Month 1
- Where
- 3 sites in Canada
- Volunteers
- 660 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan
Ankylosing spondylitis (AS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are the most common rheumatic diseases dealt with rheumatologists in Taiwan.
- Conditions
- Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ankylosing Spondylitis
- Trial name
- NCT00747578
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- Taichung Veterans General Hospital
Rheumatoid Arthritis
A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA
This is a Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between CT-P13 SC and CT-P13 IV in Patients with Active Rheumatoid Arthritis (RA).
- Trial name
- NCT03147248
- Testing
- CT-P13
- Where
- South Korea
- Volunteers
- 407 people
- Sponsor
- Celltrion
Autoimmune Diseases, Inflammatory Bowel Diseases
Chronic Inflammatory Disease, Lifestyle and Risk of Disease
Chronic inflammatory diseases (CID) - including inflammatory bowel diseases (Crohn's disease and ulcerative colitis), rheumatic conditions (rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis), inflammatory skin…
- Conditions
- Autoimmune Diseases, Inflammatory Bowel Diseases, Crohn Disease (CD), Ulcerative Colitis (UC)
- Trial name
- PROCID-DCH (NCT03456206)
- Testing
- Intake of red and processed meat and fibres, Lifestyle factors independently or combined
- Where
- Denmark
- Volunteers
- 57,053 people
- Sponsor
- University of Southern Denmark
Rheumatoid Arthritis
Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis
This study is designed to evaluate the efficacy and safety of tofacitinib modified release formulation (11mg QD) versus tofacitinib modified release formulation plus continued methotrexate treatment in subjects with moderate to…
- Trial name
- NCT02831855
- Testing
- CP-690,550, Methotrexate
- Where
- 136 sites in United States, Australia and 14 more
- Volunteers
- 694 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)
The purpose of this study is to study serum levels of Abatacept after subcutaneous dosing in subjects with RA.
- Trial name
- NCT00254293
- Testing
- Abatacept
- Where
- 5 sites in United States
- Volunteers
- 87 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients
This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single intravenous and subcutaneous doses of CFZ533 in healthy subjects and intravenous doses in rheumatoid…
- Trial name
- NCT02089087
- Testing
- CFZ533
- Where
- 6 sites in United States, Taiwan
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis (RA
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
A Phase I, open-label study of CLN-978 in patients with treatment-refractory rheumatoid arthritis.
- Trial name
- NCT06994143
- Testing
- CLN-978
- Where
- 4 sites in Germany, Italy
- Volunteers
- 37 people
- Sponsor
- Cullinan Therapeutics Inc.
Rheumatoid Arthritis
A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
The RESOLVE study is a two-part, randomized, double-blind, multi-center, placebo-controlled study of the safety, dose-range finding confirmation, and efficacy of 4 (Part A) and 12 weeks (Part B) of treatment with AP1189 in adult…
- Trial name
- RESOLVE (NCT05604885)
- Testing
- AP1189, 60 mg, AP1189, 80 mg, AP1189, 100 mg
- Where
- Moldova
- Volunteers
- 125 people
- Sponsor
- SynAct Pharma Aps
Osteoarthritis, Arthritis, Rheumatoid
Safety and Efficacy of Mobic Inj. (Meloxicam) for the Patients With OA or RA: Observational Study
The main objective of this PMS study was to monitor and assess the safety of Mobic® intramuscular injection (7.5mg ~ 15mg, q.d.) up to 3 days (in case of need for prolonged treatment, switch to Mobic® capsule therapy was…
- Trial name
- NCT00612885
- Where
- 11 sites in South Korea
- Volunteers
- 425 people
- Sponsor
- Boehringer Ingelheim
Arthritis, Rheumatoid
Phase II Study Evaluating the Safety and Efficacy of GSK315234A in Patients With Rheumatoid Arthritis
This is a randomized, double-blinded, placebo-controlled adaptive, dose finding study to investigate the safety, tolerability, PK, PD and efficacy of single and repeat intravenous infusions of GSK315243A in patients with active…
- Trial name
- NCT00674635
- Testing
- GSK3152314A
- Where
- 19 sites in Australia, New Zealand and 3 more
- Volunteers
- 135 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis, Healthy Controls
Subunit Vaccine Against Herpes Zoster in RA Patients Treated With JAK-inhibitors (VACCIMIL-ZOSTER)
Background. A new subunit vaccine against herpes zoster (HZ) has recently been approved for vaccination of adults i in Sweden. This vaccine (Shingrix) elicits a strong cellular and humoral immune response in healthy adults…
- Trial name
- NCT03886038
- Testing
- Shingrix
- Where
- Sweden
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Region Skane